Regeneron Pharmaceuticals said that European officials recommended granting marketing authorization for its colorectal cancer treatment, Zaltrap. The injectable drug would be used to treat adults. The US Food and Drug Administration approved Zaltrap in August, and marketing authorization applications are under review with other agencies around the world, Regeneron said.
Unlimited access to BostonGlobe.com for only 99 cents for the first 4 weeks.Sign up
Are you a home delivery subscriber?
Get FREE access as part of your print subscriptionStart Here
Contact us for help